Developer docs
API playgroundTry for free, no card

Search company profiles

HDBuzz

Full company profile

uuid002sqqq

Namestring
HDBuzz
Legal namestring
HDBuzz
Websiteurl
en.hdbuzz.net
Company typeenum
Private
Founded yearint
2011
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersPerú, Colombia
HQ citystring
Perú
HQ countrystring
Colombia
HQ regionstring
Latin America
Markets served

Serves global market

Keyword5 values
Huntington's disease news, medical research news, scientific communication, clinical trial tracking, health information platform
Industry1 code
PRIMARYHLACANAM
DTx/SaMD Evidence, Outcomes & Real-World Data (RWE) Platforms
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
NAICS code1 code
  • Information51
SIC code1 code
  • Services-Misc Health & Allied Services, Nec8090
Product category
Health & Medical Research News
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Donations and Grants
TypeOthers
Description

HDBuzz is funded through donations and grants. The site operates as a non-profit scientific communication service. The Funding page explains their financial model ensures neutrality and reliability.

en.hdbuzz.net
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Operations, Marketing or Sales, Technology or R&D
Pricing details1 tier
1Free access to all HDBuzz content
ModelFreemiumBilling cadenceOthers
Notes

All content is free; donations accepted but not required. Content shared under Creative Commons License allowing free redistribution.

en.hdbuzz.net
GTM typeB2C
B2C
Offering typeDigital Commerce or Conte…
Digital Commerce or Content
Core offering1 text field

HDBuzz is a non-profit online publishing platform that produces and distributes Huntington's disease research news in plain language, written by scientists for the global HD community. The platform publishes articles, conference coverage, and clinical trial updates, and supports a Trial Tracker database covering active HD drug development programs. All content is freely accessible under Creative Commons licensing and distributed in 12+ languages.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Reached 329,000 people in 2025 with independent HD research news
Product overview1 text field

HDBuzz is a unified digital research news platform providing Huntington's disease (HD) information in plain language, written by scientists for the global HD community. The core offering consists of the HDBuzz Research News Platform delivering articles, conference coverage, and clinical trial updates, supported by the HDBuzz Trial Tracker database. Additional services include a Glossary resource, multilingual content in 12+ languages, the HDBuzz Prize for Young Science Writers competition, and annual reports. The platform disseminates content through its website, social media channels (Instagram, Bluesky, Facebook, YouTube), RSS Feed, and email subscriptions.

Product and service5 records
1HDBuzz Research News Platform
CategoryHealth News Platform
Description

A digital news platform providing Huntington's disease research news in plain language, written by scientists for the global HD community. Features articles, clinical trial updates, and conference coverage.

2HDBuzz Trial Tracker
CategoryClinical Trial Tracking
Description

A curated database tracking Huntington's disease clinical trials, including drug development programs from companies like uniQure, Roche, Skyhawk Therapeutics, Novartis/PTC Therapeutics, Wave Life Sciences, Vico Therapeutics, Alnylam Pharmaceuticals, and SOM Biotech, with trial status and timeline information.

3HDBuzz Glossary
CategoryEducational Resource
Description

An educational reference resource explaining Huntington's disease terminology and scientific concepts in accessible language.

4HDBuzz Multilingual Content
CategoryMultilingual Content
Description

Research news articles translated into 12+ languages including Simplified Chinese, Dutch, French, German, Italian, Korean, Persian, Polish, Portuguese, Russian, and Spanish.

5HDBuzz Prize for Young Science Writers
CategoryWriting Competition
Description

An annual competition for early-career researchers to write about Huntington's disease in accessible language, with monetary prizes and global publication of winning entries, supported by the Hereditary Disease Foundation.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-06-12
Description

Huntington Study Group is an organization with many years of experience running HD clinical trials. They partnered with Spark/Roche to carry out the SPK-10001/RG6662 gene therapy trial. HDBuzz covers their activities and trial recruitment information.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

CHDI Foundation is described as the biggest funder and driver of HD research worldwide. HDBuzz provides coverage of CHDI's annual Huntington's Disease Therapeutics Conference, with HDBuzz staff attending and providing live updates. This is a key partnership for disseminating HD research findings to the broader community.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

The Hereditary Disease Foundation provides financial support for the annual HDBuzz Prize for Young Science Writers competition, encouraging early-career researchers to communicate HD science in accessible language.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

NORD is a broad umbrella advocacy and information organization for rare diseases, including Huntington's disease. It serves a similar patient-information function but across hundreds of conditions rather than specializing in HD.

2Friedreich's Ataxia Research Alliance (FARA)
TypeDirect peer
Description

FARA is a rare-disease organization that combines patient community support with research dissemination for Friedreich's ataxia, a hereditary neurological disease. Its blend of advocacy, scientific communication, and patient engagement parallels HDBuzz's model in a closely comparable rare-disease context.

3The Michael J. Fox Foundation for Parkinson's Research
TypeDirect peer
Description

MJFF combines Parkinson's research funding, patient education, and plain-language dissemination of trial and therapeutic news. Its hybrid research/communication model for a specific neurodegenerative disease community closely mirrors HDBuzz's positioning.

4Orphanet
TypeBroad incumbent
Description

Orphanet is a pan-European reference portal for rare diseases and orphan drugs, providing structured disease and trial information including for Huntington's disease. Its encyclopedic, multi-disease scope contrasts with HDBuzz's disease-specialized editorial approach.

TypeBroad incumbent
Description

CHDI is described as the largest funder of HD research globally and a strategic partner of HDBuzz. Although CHDI funds drug discovery rather than operating a public news platform, it is the dominant incumbent in the HD information ecosystem and shapes editorial context.

TypeDirect peer
Description

BioNews is the parent company behind dozens of 'Disease News Today' sites (e.g., SMA News Today, Parkinson's News Today, ALS News Today) that deliver plain-language research news for rare and chronic disease communities. Its vertical-specific, patient-focused model is structurally identical to HDBuzz's approach.

7Alzforum
TypeDirect peer
Description

Alzforum is a scientist-written research news platform covering Alzheimer's disease and related neurodegenerative disorders. It is the closest analog to HDBuzz: a free, independent, expert-authored news service serving patients, families, and clinicians in a specific neurodegenerative disease community.

TypeDirect peer
Description

Cure SMA supports patients with spinal muscular atrophy and funds/disseminates research updates. Like HDBuzz, it operates as a patient-facing hub for plain-language scientific news in a rare genetic neurological disease with active therapeutic development.

TypeDirect peer
Description

ALS TDI conducts and disseminates ALS research while maintaining patient and clinician-facing communication. The hybrid research-plus-translation model for a specific neurodegenerative disease community is structurally analogous to HDBuzz.

TypeBroad incumbent
Description

HSG is a longstanding clinical research cooperative running HD trials (e.g., the Spark/Roche SPK-10001/RG6662 gene therapy program). Its trial-information dissemination role overlaps with HDBuzz's Trial Tracker, though HSG focuses on investigator-facing rather than patient-facing communication.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

HDBuzz

Health & Medical Research Newsen.hdbuzz.net

HDBuzz firmographics

Firmographics
Name
HDBuzz
Legal name
HDBuzz
Website
https://en.hdbuzz.net
Company type
Private
Founded year
2011
Operating status
Operating
Headcount range
1–10 employees
Ownership category
akta.pro rank

HDBuzz industry classification

Industry
Product category
Health & Medical Research News
NAICS
Information (51)
SIC
Services-Misc Health & Allied Services, Nec (8090)
akta.pro industry
PRIMARYHLACANAM
DTx/SaMD Evidence, Outcomes & Real-World Data (RWE) Platforms
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)

Keywords

  • Huntington's disease news
  • Medical research news
  • Scientific communication
  • Clinical trial tracking
  • Health information platform

Where HDBuzz is headquartered

Location

Headquarters

HQ city
Perú
HQ country
Colombia
HQ region
Latin America

Markets served

HDBuzz business model

Business model
GTM type
B2C
Offering type
Digital Commerce or Content
Cost components
Personnel, Operations, Marketing or Sales, Technology or R&D

Revenue model

  1. Donations and Grants: HDBuzz is funded through donations and grants. The site operates as a non-profit scientific communication service. The Funding page explains their financial model ensures neutrality and reliability.

Pricing tiers

ModelBillingPrice
FreemiumOthersFree access to all HDBuzz content

Go-to-market motion1 record

Distribution channels5 records

Marketing channels7 records

HDBuzz product offering

Product offering

Core offering

HDBuzz is a non-profit online publishing platform that produces and distributes Huntington's disease research news in plain language, written by scientists for the global HD community. The platform publishes articles, conference coverage, and clinical trial updates, and supports a Trial Tracker database covering active HD drug development programs. All content is freely accessible under Creative Commons licensing and distributed in 12+ languages.

Product overview

HDBuzz is a unified digital research news platform providing Huntington's disease (HD) information in plain language, written by scientists for the global HD community. The core offering consists of the HDBuzz Research News Platform delivering articles, conference coverage, and clinical trial updates, supported by the HDBuzz Trial Tracker database. Additional services include a Glossary resource, multilingual content in 12+ languages, the HDBuzz Prize for Young Science Writers competition, and annual reports. The platform disseminates content through its website, social media channels (Instagram, Bluesky, Facebook, YouTube), RSS Feed, and email subscriptions.

Differentiator

Problem solved

Functional benefit

Products and services

  • HDBuzz Research News Platform A digital news platform providing Huntington's disease research news in plain language, written by scientists for the global HD community. Features articles, clinical trial updates, and conference coverage.
  • HDBuzz Trial Tracker A curated database tracking Huntington's disease clinical trials, including drug development programs from companies like uniQure, Roche, Skyhawk Therapeutics, Novartis/PTC Therapeutics, Wave Life Sciences, Vico Therapeutics, Alnylam Pharmaceuticals, and SOM Biotech, with trial status and timeline information.
  • HDBuzz Glossary An educational reference resource explaining Huntington's disease terminology and scientific concepts in accessible language.
  • HDBuzz Multilingual Content Research news articles translated into 12+ languages including Simplified Chinese, Dutch, French, German, Italian, Korean, Persian, Polish, Portuguese, Russian, and Spanish.
  • HDBuzz Prize for Young Science Writers An annual competition for early-career researchers to write about Huntington's disease in accessible language, with monetary prizes and global publication of winning entries, supported by the Hereditary Disease Foundation.

Quantifiable outcome

  • Reached 329,000 people in 2025 with independent HD research news

Companies that use HDBuzz

Customer profile

Named customers3 records

Segments3 records

Ideal customer profiles3 records

HDBuzz technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

HDBuzz partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core and minor.

  • Huntington Study GroupcoreStrategic or Co-development Partner · 12 June 2025Huntington Study Group is an organization with many years of experience running HD clinical trials. They partnered with Spark/Roche to carry out the SPK-10001/RG6662 gene therapy trial. HDBuzz covers their activities and trial recruitment information.
  • CHDI FoundationcoreStrategic or Co-development PartnerCHDI Foundation is described as the biggest funder and driver of HD research worldwide. HDBuzz provides coverage of CHDI's annual Huntington's Disease Therapeutics Conference, with HDBuzz staff attending and providing live updates. This is a key partnership for disseminating HD research findings to the broader community.
  • Hereditary Disease FoundationminorStrategic or Co-development PartnerThe Hereditary Disease Foundation provides financial support for the annual HDBuzz Prize for Young Science Writers competition, encouraging early-career researchers to communicate HD science in accessible language.

Scale indicators3 records

Recent moves6 records

Expansion highlights4 records

HDBuzz competitors and assessment

Company assessment

Broad incumbents

  • NORD (National Organization for Rare Disorders): NORD is a broad umbrella advocacy and information organization for rare diseases, including Huntington's disease. It serves a similar patient-information function but across hundreds of conditions rather than specializing in HD.
  • Orphanet: Orphanet is a pan-European reference portal for rare diseases and orphan drugs, providing structured disease and trial information including for Huntington's disease. Its encyclopedic, multi-disease scope contrasts with HDBuzz's disease-specialized editorial approach.
  • CHDI Foundation: CHDI is described as the largest funder of HD research globally and a strategic partner of HDBuzz. Although CHDI funds drug discovery rather than operating a public news platform, it is the dominant incumbent in the HD information ecosystem and shapes editorial context.
  • Huntington Study Group: HSG is a longstanding clinical research cooperative running HD trials (e.g., the Spark/Roche SPK-10001/RG6662 gene therapy program). Its trial-information dissemination role overlaps with HDBuzz's Trial Tracker, though HSG focuses on investigator-facing rather than patient-facing communication.

Direct peers

  • Friedreich's Ataxia Research Alliance (FARA): FARA is a rare-disease organization that combines patient community support with research dissemination for Friedreich's ataxia, a hereditary neurological disease. Its blend of advocacy, scientific communication, and patient engagement parallels HDBuzz's model in a closely comparable rare-disease context.
  • The Michael J. Fox Foundation for Parkinson's Research: MJFF combines Parkinson's research funding, patient education, and plain-language dissemination of trial and therapeutic news. Its hybrid research/communication model for a specific neurodegenerative disease community closely mirrors HDBuzz's positioning.
  • BioNews: BioNews is the parent company behind dozens of 'Disease News Today' sites (e.g., SMA News Today, Parkinson's News Today, ALS News Today) that deliver plain-language research news for rare and chronic disease communities. Its vertical-specific, patient-focused model is structurally identical to HDBuzz's approach.
  • Alzforum: Alzforum is a scientist-written research news platform covering Alzheimer's disease and related neurodegenerative disorders. It is the closest analog to HDBuzz: a free, independent, expert-authored news service serving patients, families, and clinicians in a specific neurodegenerative disease community.
  • Cure SMA: Cure SMA supports patients with spinal muscular atrophy and funds/disseminates research updates. Like HDBuzz, it operates as a patient-facing hub for plain-language scientific news in a rare genetic neurological disease with active therapeutic development.
  • ALS Therapy Development Institute: ALS TDI conducts and disseminates ALS research while maintaining patient and clinician-facing communication. The hybrid research-plus-translation model for a specific neurodegenerative disease community is structurally analogous to HDBuzz.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

HDBuzz social profiles

Digital presence

HDBuzz financial estimates

Financial estimate

Revenue estimate

Valuation estimate

HDBuzz leadership team

Management profile

Number of profiles

Profiles5 records

HDBuzz funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

HDBuzz M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about HDBuzz

What does HDBuzz do?

HDBuzz is a non-profit online publishing platform that produces and distributes Huntington's disease research news in plain language, written by scientists for the global HD community. The platform publishes articles, conference coverage, and clinical trial updates, and supports a Trial Tracker database covering active HD drug development programs. All content is freely accessible under Creative Commons licensing and distributed in 12+ languages.

Is HDBuzz a public or private company?

HDBuzz is a private company. It is classified as nonprofit foundation owned and is currently operating.

When was HDBuzz founded?

HDBuzz was founded in 2011. It employs 1 to 10 people.

Where is HDBuzz based?

HDBuzz is headquartered in Perú, Colombia, in the Latin America region.

How does HDBuzz make money?

One revenue line is on record: donations and Grants.

Who are HDBuzz's main competitors?

Broad incumbents on record are NORD (National Organization for Rare Disorders), Orphanet, CHDI Foundation and Huntington Study Group. Direct peers are Friedreich's Ataxia Research Alliance (FARA), The Michael J. Fox Foundation for Parkinson's Research, BioNews, Alzforum, Cure SMA and ALS Therapy Development Institute.

Does HDBuzz have an API?

No public API is recorded for HDBuzz.

What industry is HDBuzz in?

HDBuzz's product category is Health & Medical Research News. Its primary akta.pro industry code is HLACANAM, DTx/SaMD Evidence, Outcomes & Real-World Data (RWE) Platforms. Its NAICS code is 51 and its SIC code is 8090.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals